(i24News-Xinhua-China) Israel's Bonus BioGroup announced Wednesday that preliminary findings from a clinical trial of the drug MesenCure for the treatment of corona patients in life-threatening respiratory distress were "very impressive." Nine of the ten patients suffered from background diseases as well, yet each of them treated with MesenCure showed marked improvements. Prior to treatment, as much as 55% of a person's lung area showed inflammation in chest x-rays. Within five days of beginning a course of the drug, that figure dropped to 15%, while it was almost normal one month later. The new drug, consisting of adipose-derived stem cells from healthy donors, is transmitted to the patients by blood transfusion. The ten Covid-19 patients in the trial all suffered from acute respiratory distress, severe pneumonia, and dangerous immune response. All the patients were discharged from the hospital after one day on average since the treatment ended.
2021-05-31 00:00:00Full ArticleBACK Visit the Daily Alert Archive